Strategy • Innovation • Biotech

Maryana
Breitman,
PhD, MBA

Strategic advisor to biotechnology and pharmaceutical companies navigating complex transactions, growth strategies, and innovation challenges.

Senior biopharmaceutical strategy advisor with experience across global pharmaceutical leadership, biotechnology equity research, and scientific innovation. Advises biopharma executives, boards, and investors on corporate strategy, transactions, portfolio decision-making, and long-term value creation.

Start a Conversation
Maryana Breitman
About

Two Decades of Shaping
Biotech Strategy

With over 20 years of experience at the intersection of biotechnology, pharmaceuticals, and finance, I bring a rare combination of scientific rigor and business acumen to every engagement.

My career spans leadership roles at Pfizer, equity research at Goldman Sachs and UBS, and entrepreneurial ventures in biotech. This unique perspective allows me to bridge the gap between scientific innovation and strategic business outcomes.

I specialize in helping organizations navigate high-stakes decisions—from M&A integration and corporate strategy to launching novel therapeutic programs in competitive markets.

My work integrates deep scientific expertise, capital markets perspective, and operating-level strategy within large pharmaceutical organizations.

20+
Years Experience
4
Languages
PhD
Biochemistry & Structural Biology
MBA
Columbia Business
Services

How I Can Help

Tailored strategic counsel for organizations seeking to grow, transform, and compete in the life sciences sector.

Corporate Strategy

Portfolio optimization, competitive positioning, and long-range strategic planning for biotech and pharma companies.

M&A Advisory

Due diligence, deal structuring, integration planning, and post-merger value creation in the life sciences space.

Innovation & R&D

Pipeline assessment, therapeutic area strategy, and translating scientific breakthroughs into commercial opportunities.

Investor Relations

Equity story development, investor communications, and capital markets strategy grounded in deep sector expertise.

Business Development & Licensing

Strategic partnerships, in-licensing and out-licensing opportunities, deal evaluation, and collaboration frameworks.

Competitive & Market Positioning

Comprehensive market analysis, competitive landscape assessment, and strategic positioning for therapeutic assets and corporate portfolios.

Executive & Board Advisory

Decision support for C-suite executives and boards of directors on high-stakes strategic, transactional, and portfolio decisions.

Experience

Career Highlights

A track record of leadership across Wall Street, Big Pharma, and entrepreneurial biotech ventures.

Oct 2019 – Present

Director

Pfizer — New York City Metropolitan Area

Leading strategic initiatives in one of the world's largest pharmaceutical companies, driving corporate strategy across multiple therapeutic areas.

Advises senior leadership on enterprise-level strategy, innovation platforms, portfolio priorities, and long-term growth opportunities within a global pharmaceutical organization.

Pharmaceuticals Strategy Financial Analysis Drug Development
Jul 2018 – Oct 2019

Biotechnology Equity Research

Goldman Sachs — Greater New York City Area

Covered biotechnology equities, providing institutional investors with deep analytical insights on therapeutic pipelines, clinical data, and market dynamics.

Analyzed public biotechnology companies, clinical programs, and industry trends; developed investment theses and engaged with management teams and institutional investors.

Equity Research Biotech Capital Markets Corporate Finance
Jul 2016 – Jun 2018

Biotechnology Equity Research

Deutsche Bank

Conducted biotechnology equity research, covering pharmaceutical and biotech companies for institutional investors with focus on clinical data analysis and market dynamics.

Evaluated biotechnology companies across therapeutic areas, analyzing clinical data, regulatory pathways, and corporate strategies for institutional investor clients.

Equity Research Financial Analysis Corporate Finance
Mar 2015 – Jun 2016

Associate Director

UBS

Conducted rigorous financial analysis and company valuations across the biotechnology sector for global institutional clients.

Covered biotechnology companies across therapeutic areas, evaluating clinical data, regulatory pathways, and commercial strategies.

Pharmaceuticals Strategy Financial Forecasting
2009 – 2015

Founder & CEO

MBMR Biolabs Inc. — New York, NY

Founded and led an early-stage biotechnology company, advancing novel therapeutic approaches from bench to preclinical development. Successfully licensed technology to one of top-10 global life science/diagnostics companies.

Founded and led a biotechnology company focused on translational science and therapeutic development.

Entrepreneurship Drug Development Fundraising
2008 – 2010

Research Fellow

Memorial Sloan-Kettering Cancer Center — New York, NY

Executed breakthrough research resulting in a foundational publication evaluated as top 1% in biological physics. Co-authored “Mechanism for Arf-1 Dependent Recruitment of Coatomer to Membranes” in Cell (2012).

Research Structural Biology Drug Development
Education & Credentials

Academic Foundation

Princeton University

Bachelor of Arts
Molecular Biology
Art History

Cornell University

PhD Biochemistry and Structural Biology
X-ray Crystallography, Molecular Biology, Cell Biology, Enzymology
Genetics and Biochemistry Tutor, Film Club President

Columbia Business School

Master of Business Administration
Finance & Financial Management Services
Private Equity/Venture Capital Club, Healthcare Association

Licenses & Certifications

FINRA Series 7, 63, 66, 87

Languages

Russian English French German
Publications & Thought Leadership

Research & Insights

Selected publications and contributions to the field.

Research Publication

A Structure-Based Mechanism for Arf1-Dependent Recruitment of Coatomer to Membranes

Co-authored research published in Cell (2012), exploring structural mechanisms of membrane trafficking and coatomer recruitment.

PubMed DOI
Perspective

Capital Markets & Industry

A capital-markets-informed approach to biopharmaceutical strategy.

Maryana brings a capital-markets-informed approach to biopharmaceutical strategy, shaped by her experience in biotechnology equity research and ongoing engagement with public company leadership, investors, and industry stakeholders.

Her work includes sector and company-level analysis, evaluation of clinical and regulatory risk, strategic positioning ahead of value-defining milestones, and engagement with executive teams and boards.

Engagements

Advisory Engagements

Maryana works with biopharmaceutical executive teams, boards of directors, corporate strategy and business development groups, as well as investors and financial sponsors. Engagements are focused, confidential, and tailored to high-stakes strategic decisions.

Thought Leadership

Speaking & Engagements

Available for select engagements including executive strategy sessions, board briefings, industry panels, and private workshops. Topics include biopharmaceutical strategy, innovation management, portfolio optimization, and value creation.

Testimonials

What Colleagues Say

“

Maryana brings an unmatched combination of scientific depth and strategic vision. Her ability to translate complex biotech landscapes into actionable strategies is extraordinary.

Senior Executive
Pharmaceutical Industry
“

A rare talent who understands both the science and the business. Her M&A advisory work was instrumental in driving our acquisition strategy forward with confidence.

Managing Director
Investment Banking
Get in Touch

Let’s Work Together

Ready to discuss how strategic advisory can accelerate your organization’s growth? I’d love to hear from you.

Contact Information

contact@maryanabreitman.com
New York, New York
LinkedIn Profile